121 related articles for article (PubMed ID: 26403512)
1. Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy.
Franceschini D; Paiar F; Saieva C; Bonomo P; Agresti B; Meattini I; Greto D; Mangoni M; Meacci F; Loi M; Zei G; Livi L; Biti G
Radiol Med; 2016 Mar; 121(3):229-37. PubMed ID: 26403512
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of anaemia at different treatment times in patients with locally advanced head and neck cancer treated with surgery and postoperative radiotherapy.
Dietl B; Marienhagen J; Schäfer C; Kölbl O
Clin Oncol (R Coll Radiol); 2007 May; 19(4):228-33. PubMed ID: 17433968
[TBL] [Abstract][Full Text] [Related]
3. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).
Ghadjar P; Pöttgen C; Joos D; Hayoz S; Baumann M; Bodis S; Budach W; Studer G; Stromberger C; Zimmermann F; Kaul D; Plasswilm L; Olze H; Bernier J; Wust P; Aebersold DM; Budach V
Strahlenther Onkol; 2016 Aug; 192(8):552-60. PubMed ID: 27323753
[TBL] [Abstract][Full Text] [Related]
4. Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy.
Gomez-Millan J; Pajares B; Perez-Villa L; Carnero A; Alvarez M; De Luque V; Rivas F; Trigo JM; Toledo MD; Alba E; Medina JA
BMC Cancer; 2016 Oct; 16(1):829. PubMed ID: 27793200
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
[TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Haddad R; O'Neill A; Rabinowits G; Tishler R; Khuri F; Adkins D; Clark J; Sarlis N; Lorch J; Beitler JJ; Limaye S; Riley S; Posner M
Lancet Oncol; 2013 Mar; 14(3):257-64. PubMed ID: 23414589
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bone or cartilage invasion of locally advanced head and neck cancers.
Do L; Syed N; Puthawala A; Azawi S; Williams R; Vora N
Am J Clin Oncol; 2010 Dec; 33(6):591-4. PubMed ID: 20065851
[TBL] [Abstract][Full Text] [Related]
8. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Choe KS; Haraf DJ; Solanki A; Cohen EE; Seiwert TY; Stenson KM; Blair EA; Portugal L; Villaflor VM; Witt ME; Vokes EE; Salama JK
Cancer; 2011 Oct; 117(20):4671-8. PubMed ID: 21671479
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment prognostic factors influencing distant metastasis-free survival in locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy.
Jeremić B; Miličić B
Am J Clin Oncol; 2009 Oct; 32(5):483-7. PubMed ID: 19506455
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of hemoglobin levels before and after surgery as well as before and after radiochemotherapy for head and neck tumors.
Reichel O; Panzer M; Wimmer C; Dühmke E; Kastenbauer E; Suckfüll M
Eur Arch Otorhinolaryngol; 2003 May; 260(5):248-53. PubMed ID: 12750913
[TBL] [Abstract][Full Text] [Related]
12. Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?
Akagunduz OO; Savas R; Yalman D; Kocacelebi K; Esassolak M
Nucl Med Biol; 2015 Nov; 42(11):899-904. PubMed ID: 26275933
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
14. CT-based follow-up following radiotherapy or radiochemotherapy for locally advanced head and neck cancer; outcome and development of a prognostic model for regional control.
Nevens D; Vantomme O; Laenen A; Hermans R; Nuyts S
Br J Radiol; 2016 Dec; 89(1068):20160492. PubMed ID: 27710014
[TBL] [Abstract][Full Text] [Related]
15. Extent of pathologic extracapsular extension and outcomes in patients with nonoropharyngeal head and neck cancer treated with initial surgical resection.
Prabhu RS; Hanasoge S; Magliocca KR; Moeller BJ; Milas ZL; Hall WA; El-Deiry M; Wadsworth JT; Higgins KA; Beitler JJ
Cancer; 2014 May; 120(10):1499-506. PubMed ID: 24510454
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
17. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
[TBL] [Abstract][Full Text] [Related]
18. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U
Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058
[TBL] [Abstract][Full Text] [Related]
19. Comorbidity is a prognostic factor in elderly patients with head and neck cancer.
Sanabria A; Carvalho AL; Vartanian JG; Magrin J; Ikeda MK; Kowalski LP
Ann Surg Oncol; 2007 Apr; 14(4):1449-57. PubMed ID: 17235712
[TBL] [Abstract][Full Text] [Related]
20. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]